Biomarker in Irritable Bowel Diseases Diagnostic Market: Introduction
- Irritable or Inflammatory bowel disease (IBD) is a chronic disease, which is used to describe disorders that involve chronic inflammation of the digestive tract. Types of IBD include ulcerative colitis and Crohn's disease. Fecal and serologic biomarkers can be used in the diagnosis and management of inflammatory bowel disease (IBD).
Are you a start-up willing to make it big in the business? Grab an exclusive PDF Brochure of this report
Key Drivers and Restraints of Global Biomarker in Irritable Bowel Diseases Diagnostic Market
- High prevalence of IBD boost the market. In Europe, an estimated 2.5 to 3 million people are affected by inflammatory bowel disease per year. Highest incidence and prevalence of IBD is observed in Scandinavia and the U.K. According to IBD Support Australia Incorporated, around 61,000 people in Australia are affected by inflammatory bowel disease, of which around 28,000 people are affected by Crohn’s disease and 33,000 are affected by ulcerative colitis.
- Newer biomarkers are expected to offer significant opportunities. According to a study presented at Digestive Disease Week, the Mucosal Healing Index, a serum-based biomarker assay, demonstrated efficacy in identifying mucosal inflammation and similar accuracy to fecal calprotectin in patients with Crohn’s disease.
- However, economic barriers in underdeveloped & developing countries may hamper the market. A huge diversity of health care quality is observed in different geographic areas in Asia, Africa, Latin America, and the Middle East owing to economic imbalance. In certain regions, limited patient access to healthcare facilities, poor physician and patient awareness about disease, and limited availability of diagnostic modalities may delay diagnosis. This is estimated to hamper the in-vitro inflammatory bowel disease diagnostic market during the forecast period.
To gauge the scope of customization in our reports, Ask for a Sample
Stool-based biomarkers to dominate global biomarker in irritable bowel diseases diagnostic market
- Based on type, the global biomarker in irritable bowel diseases diagnostic market can be divided into blood-based biomarker and stool-based biomarker. The blood-based biomarker segment can be further sub-segmented into C-reactive protein, erythrocyte sedimentation rate, and others. The stool-based biomarkers segment can be divided into faecal calprotectin, faecal lactoferrin, and others
- In stool-based biomarkers primarily calprotectin is used to detect irritable bowel diseases. Surge in FDA approvals for various assays and product advances are likely to boost the segment in the near future. BÜHLMANN fCAL turbo is an in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin. Gentian has, in cooperation with its partner BÜHLMANN, has been delivering the BÜHLMANN fCAL turbo to the market since 2016 and recorded an 81% sales growth in 2018, with sales reaching US$ 1.02 Mn.
Hospitals segment to expand significantly
- Based on end user, the global biomarker in irritable bowel diseases diagnostic market can be divided into diagnostic laboratories, hospitals and research institutes.
- The diagnostic laboratories segment dominates the biomarker in irritable bowel diseases diagnostic market. Rise in awareness about preventive health and increase in targeted diseases boost the segment.
- However, the hospitals segment is expected to gain market share during the forecast period and expand at a significant CAGR during that time. Expansion of the segment can be attributed to a rise in the rate of hospitalization for inflammatory bowel diseases and wide range of services offered by hospitals at a single site. Rise in cases of irritable bowel diseases boosts the segment. Internationally, the incidence of IBD is around 0.5 to 24.5 cases per 100,000 person-years for ulcerative colitis and 0.1 to 16 cases per 100,000 person-years for Crohn’s disease.
North America to dominate global biomarker in irritable bowel diseases diagnostic market
- In terms of region, the global biomarker in irritable bowel diseases diagnostic market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
- In terms of revenue, North America dominated the biomarker in irritable bowel diseases diagnostic market in 2019, followed by Europe. High prevalence of diseases and well-established health care infrastructure that enables proper diagnosis of IBD are responsible for the high market share held by the region. According to a paper published in Gastroenterology & Hepatology journal, in 2017, there were 6·8 million cases of IBD globally, and the highest prevalence rate in 2017 occurred in high-income North America.
- However, the market in Asia Pacific is estimated to expand at a rapid pace during the forecast period primarily due to a rise in the prevalence of disorders and an increase in awareness about treatment in the region. Majority of countries in Asia Pacific are economically developing and numerous players are making significant investments in the region. These factors boost the market in Asia Pacific. Rise in technological advancements in countries in terms of health care and medical research is anticipated to fuel the market in the region. The incidence of Crohn’s disease has been increasing in countries in Asia in the last few years. A study conducted in 2013 reported the incidence of IBD at 0.54 to 3.44 per 100,000 in the region.
Key Manufacturers Operating in Market
The global biomarker in irritable bowel diseases diagnostic market was highly fragmented in 2019. Key manufacturers operating in the global market are:
- DiaSorin S.p.A.
- F. Hoffmann-La Roche Ltd
- Siemens Healthineers AG
- Abbott Laboratories
- Quidel Corporation
- BÜHLMANN Laboratories AG
- American Laboratory Products Company (ALPCO)
- Certest Biotec SL.
- Biosystems S.A.
Biomarker in Irritable Bowel Diseases Diagnostic Market: Research Scope
Biomarker in Irritable Bowel Diseases Diagnostic Market, by Type
- Blood based Biomarker
- C-reactive protein
- Erythrocyte sedimentation rate
- Stool based Biomarker
- Faecal calprotectin
- Faecal lactoferrin
Biomarker in Irritable Bowel Diseases Diagnostic Market, by End-user
- Diagnostic Laboratories
- Research Institutes
Biomarker in Irritable Bowel Diseases Diagnostic Market, by Region
- North America
- Rest of Europe
- Asia Pacific
- Australia & New Zealand
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of Middle East & Africa
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.